Search Results 61-70 of 17192 for GnRH
... GnRH agonist at least 4 weeks prior to the first dose of fulvestrant. If patients have received an alternative GnRH agonist prior to study entry, they must ...
Subjects can continue to receive bisphosphonates due to metastatic bone disease or GnRH agonists if they have prostate cancer. Ongoing toxic manifestations ...
... (GnRH) analogue therapy, such as progesterone, medroxyprogesterone, progestins (megesterol), or 5-alpha reductase inhibitors (e.g., finasteride or ...
The purpose of this study is to determine the contribution of islet GLP-1 to islet function in people with and without diabetes-associated genetic variation in ...
About this study. The objectives of this study are to identify the unique individual neuro-hormonal footprint of volumetric, caloric, and hedonic ...
No ua\se of GnRH analogues, aromatase inhimitors, selective E2 or P4 receptor modulators, oral contraceptives, or immunotherapy within 3 months prior to ...
... (GnRH) analog (agonist or antagonist) prior to the first dose of study drug and must continue this therapy throughout the treatment phase * Palliative ...
... (GnRH) agonist such as goserelin or radiation-induced ovarian suppression postmenopausal status due to surgical/natural menopause is defined as meeting one ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your gift to celebrate this day advances our doctors’ lifesaving work.